MAP2K7 and cancer: Although KRAS has been an elusive target across multiple cancer types, prior early-phase studies have found promising response rates to MEK inhibitors and MEK inhibitor combinations in those patients with KRAS-mutant LGSOC.16-18 This has led to considerable interest in the use of mutation status when weighing the expected adverse effects versus benefits of MEK inhibitor therapy.